Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Operating Expenses (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Operating Expenses data on record, last reported at $36.4 million in Q3 2025.

  • For Q3 2025, Operating Expenses rose 97.85% year-over-year to $36.4 million; the TTM value through Sep 2025 reached $110.2 million, down 27.9%, while the annual FY2024 figure was $146.8 million, 16.37% up from the prior year.
  • Operating Expenses reached $36.4 million in Q3 2025 per TNXP's latest filing, up from $30.3 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $79.5 million in Q2 2024 and bottomed at $18.4 million in Q3 2024.
  • Average Operating Expenses over 3 years is $32.6 million, with a median of $30.3 million recorded in 2025.
  • Peak YoY movement for Operating Expenses: skyrocketed 174.2% in 2024, then tumbled 61.91% in 2025.
  • A 3-year view of Operating Expenses shows it stood at $31.1 million in 2023, then fell by 19.44% to $25.1 million in 2024, then soared by 45.07% to $36.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $36.4 million in Q3 2025, $30.3 million in Q2 2025, and $18.5 million in Q1 2025.